NASDAQ
MDWD

Mediwound Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Mediwound Ltd Stock Price

Vitals

Today's Low:
$7.68
Today's High:
$7.9
Open Price:
$7.68
52W Low:
$7.1
52W High:
$14.58
Prev. Close:
$7.67
Volume:
13944

Company Statistics

Market Cap.:
$72.67 million
Book Value:
4.816
Revenue TTM:
$25.99 million
Operating Margin TTM:
-34.12%
Gross Profit TTM:
$13.17 million
Profit Margin:
-55.53%
Return on Assets TTM:
-12.97%
Return on Equity TTM:
-88.29%

Company Profile

Mediwound Ltd had its IPO on 2014-03-20 under the ticker symbol MDWD.

The company operates in the Healthcare sector and Biotechnology industry. Mediwound Ltd has a staff strength of 83 employees.

Stock update

Shares of Mediwound Ltd opened at $7.68 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.68 - $7.9, and closed at $7.8.

This is a +1.69% increase from the previous day's closing price.

A total volume of 13,944 shares were traded at the close of the day’s session.

In the last one week, shares of Mediwound Ltd have slipped by -4.65%.

Mediwound Ltd's Key Ratios

Mediwound Ltd has a market cap of $72.67 million, indicating a price to book ratio of 31.7321 and a price to sales ratio of 2.4803.

In the last 12-months Mediwound Ltd’s revenue was $25.99 million with a gross profit of $13.17 million and an EBITDA of $-8166000. The EBITDA ratio measures Mediwound Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Mediwound Ltd’s operating margin was -34.12% while its return on assets stood at -12.97% with a return of equity of -88.29%.

In Q2, Mediwound Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2.2%.

Mediwound Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.07

Its diluted EPS in the last 12-months stands at $-2.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mediwound Ltd’s profitability.

Mediwound Ltd stock is trading at a EV to sales ratio of 1.7632 and a EV to EBITDA ratio of -2.5422. Its price to sales ratio in the trailing 12-months stood at 2.4803.

Mediwound Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$64.37 million
Total Liabilities
$8.31 million
Operating Cash Flow
$0
Capital Expenditure
$1.07 million
Dividend Payout Ratio
0%

Mediwound Ltd ended 2024 with $64.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $64.37 million while shareholder equity stood at $34.93 million.

Mediwound Ltd ended 2024 with $0 in deferred long-term liabilities, $8.31 million in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $51.12 million and cash and short-term investments were $51.12 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Mediwound Ltd’s total current assets stands at $58.05 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $3.82 million compared to accounts payable of $3.53 million and inventory worth $3.11 million.

In 2024, Mediwound Ltd's operating cash flow was $0 while its capital expenditure stood at $1.07 million.

Comparatively, Mediwound Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$7.8
52-Week High
$14.58
52-Week Low
$7.1
Analyst Target Price
$27.25

Mediwound Ltd stock is currently trading at $7.8 per share. It touched a 52-week high of $14.58 and a 52-week low of $14.58. Analysts tracking the stock have a 12-month average target price of $27.25.

Its 50-day moving average was $9.17 and 200-day moving average was $10.92 The short ratio stood at 5.16 indicating a short percent outstanding of 0%.

Around 2423.7% of the company’s stock are held by insiders while 2960.9% are held by institutions.

Frequently Asked Questions About Mediwound Ltd

The stock symbol (also called stock or share ticker) of Mediwound Ltd is MDWD

The IPO of Mediwound Ltd took place on 2014-03-20

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$7.91
0.38
+5.05%
$8.13
-0.68
-7.72%
$0.77
-0.03
-3.99%
$229.65
-9.25
-3.87%
$19.19
-0.37
-1.89%
$100.9
-0.25
-0.25%
$3.13
0.02
+0.64%
TrueCar Inc (TRUE)
$2.4
-0.05
-2.04%
$20.65
0.13
+0.62%
JYOTI STRUCTURES LTD. (JYOTISTRUC)
$10.9
-0.44
-3.88%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Address

42 Hayarkon Street, Yavne, Israel, 8122745